Objective:To explore the expression level of CD58/CD2 and its relationship with the clinical pathological characteristics. Methods:Among 40 patients with uterine cervix cancer and 30 CIN patients,immunohistochemistry method was used to detect the expression of CD58,and flow cytometry was used to detect the CD2 expression in peripheral blood cells,and 30 cases of hysteromyoma were collected as normal controls. Results:The expressions of CD2 and CD58 in patients with uterine cervix cancer were significantly lower than those in CIN patients and normal controls,respectively(P < 0.05). The expression levels of CD58/CD2 were different in uterine cervix cancer patients with different pathological grades,tumor size and invasion depth(P < 0.05). But there were no significant differences in uterine cervix cancer patients with different FIGO stage,age and menopause situation respectively(P > 0.05). Conclusion:The expressions of CD58/CD2 were correlated with the development of uterine cervix cancer,and they could be used as the index for evaluating treatment efficacy and prognosis,and may be the new targes for therapy.